Document:

Amendment No. 2 to Lease Lake Union Steam Plant, dated July 19, 2004

 Exhibit 10.1 
  
 AMENDMENT NO. 2 TO LEASE 
  
 LAKE UNION STEAM PLANT BUILDING 
  
 This AMENDMENT NO. 2 TO LEASE (this “Amendment”) is entered into as of the below date between ARE-1201/1208 EASTLAKE AVENUE, LLC, a Delaware
limited liability company (“Landlord”) and ZYMOGENETICS, INC., a Washington corporation (“Tenant”). 
  
 Landlord and Tenant are parties to that certain Lease dated October 4, 2002, as amended by Amendment No. 1 to Lease dated December 31, 2002. Capitalized
terms not defined herein shall have the meanings set forth in the Lease. Pursuant to Section 2.1 of the Lease, the initial term has been extended and the purpose of this Amendment is to reflect the extension. 
  
 Now, therefore, Landlord and Tenant agree as follows: 
  
 1. EXTENSION OF INITIAL TERM. Effective on May 11, 2004, expiration
date of the Initial Terms of the Lease is extended to May 10, 2019. 
  
 2. NO OTHER AMENDMENTS. Except as modified by this Amendment and by Amendment No. 1 dated December 31, 2002, the Lease remains in full force and effect and has not been modified or amended. 
  
 DATED: July 19, 2004. 
  

							
	LANDLORD:
	
	 ARE-1201/1208 Eastlake Avenue, LLC,

	 a Delaware limited liability company

		
	 By:
	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,

	 	 	 a Delaware limited partnership,

	 	 	 managing member

			
	 	 	 By:
	 	 ARE-QRS CORP.,

	 	 	 	 	 a Maryland corporation,

	 	 	 	 	 general partner

				
	 	 	 	 	 By:
	 	 /s/ Peter J. Nelson, CFO

	 	 	 	 	 	 	 Peter J. Nelson, CFO

	
	TENANT:
	
	 ZYMOGENETICS, INC.,

	 a Washington corporation

		
	 By
	 	 /s/ James A. Johnson

	 Name:
	 	  

	 Title:
	 	 Senior Vice President and Chief Financial Officer

			
	 STATE OF WASHINGTON
	  	 )

	 	  	 ) ss.

	 COUNTY OF KING
	  	 )

  
 I certify that I know or have
satisfactory evidence that James A. Johnson signed this instrument, on oath stated that he was authorized to execute the instrument and acknowledged it as the Chief Financial Officer of ZymoGenetics, Inc. to be the free and voluntary
act of such party for the uses and purposes mentioned in the instrument. 
  
 Dated: July 12, 2004. 
  

	
	 /s/ Kim M. Goplen

	 (Signature)

	
	 Notary Public

	 Title

	
	 My appointment expires July 7, 2007

  

			
	 STATE OF California
	  	 )

	 	  	 ) ss.

	 COUNTY OF Los Angeles
	  	 )

  
 I certify that I know
or have satisfactory evidence that Peter J. Nelson is the person who appeared before me, and said person acknowledged that he/she signed this instrument, on oath stated that he/she was authorized to execute the instrument and acknowledged it as the
Chief Financial Officer of ARE-QRS Corp., general partner of Alexandria Real Estate Equities, L.P., the Managing Member of ARE-1201/1208 Eastlake Avenue, LLC, to be the free and voluntary act of such party for the uses and purposes mentioned in this
instrument. 
  
 DATED: July 19, 2004. 
  

	
	 /s/ Teresa A. Flores

	 (Signature of Notary Public)

	
	 Teresa A. Flores

	 (Printed Name of Notary Public)

	 My Appointment expires: June 24, 2005

  

 2Amendment No. 2 to Lease Earl Davie Building, dated June 14, 2004

 Exhibit 10.2 
  
 AMENDMENT NO. 2 TO LEASE 
  
 EARL DAVIE BUILDING 
  
 This AMENDMENT NO. 2 TO LEASE (this “Amendment”) is entered into as of the below date between ARE-1208 EASTLAKE AVENUE, LLC, a Delaware limited
liability company (“Landlord”) and ZYMOGENETICS, INC., a Washington corporation (“Tenant”). 
  
 Landlord and Tenant are parties to that certain Lease dated October 4, 2002, as amended by Amendment No. 2 to Lease dated December 31, 2002. Capitalized
terms not defined herein shall have the meanings set forth in the Lease. Pursuant to Section 24 of the Lease, Tenant constructed the Expansion and the purpose of this Amendment is to reflect the changes to the Lease as a result of completion of the
Expansion. 
  
 Now, therefore, Landlord and Tenant agree as
follows: 
  
 1. EXPANSION RENT COMMENCEMENT DATE. The
Expansion Rent Commencement Date is May 11, 2004. Effective on the Expansion Rent Commencement Date: (a) the Base Rent is increased to $270,200.27 per month, (b) expiration date of the Initial Term of the Lease is extended to May 10, 2019, which
date is 180 months from the Expansion Rent Commencement Date, and (c) the Security Deposit required under Section 7.1 of the Lease is increased to $540,400.54. 
  

2. EXPANSION LAND AMENDMENT. Pursuant to Lease Section 24.2, Landlord and Tenant were to cooperate to cause the addition of certain real
property to the Premises (the “Expansion Land”) and in connection with that addition, Tenant was to transfer certain other real property to WSDOT. Those transactions have not yet been completed, and Landlord and Tenant agree that once they
are complete, they will execute a further amendment to the Lease to acknowledge fulfillment of the conditions in Lease Section 24.2 and to amend Lease Exhibit A to reflect the addition of the Expansion Land to the Premises. Such amendment will not
cause any change to the Lease terms set forth in paragraph 1 above. 
  
 3. NO OTHER AMENDMENTS. Except as modified by this Amendment and by Amendment No. 1 dated December 31, 2002, the Lease remains in full force and effect and has not been modified or amended. 
  
 DATED: June 14, 2004. 
  

							
	LANDLORD:
	
	 ARE-1208 Eastlake Avenue, LLC,

	 a Delaware limited liability company

		
	 By:
	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,

	 	 	 a Delaware limited partnership,

	 	 	 managing member

			
	 	 	 By:
	 	 ARE-QRS CORP.,

	 	 	 	 	 a Maryland corporation,

	 	 	 	 	 general partner

				
	 	 	 	 	 By:
	 	 /s/ Peter J. Nelson, CFO

	 	 	 	 	 	 	 Peter J. Nelson, CFO

			
	TENANT:
	
	 ZYMOGENETICS, INC.,

	 a Washington corporation

		
	 By:
	 	 /s/ James A. Johnson

	 Name:
	 	 James A. Johnson

	 Title:
	 	 Senior Vice President and Chief Financial Officer

  

			
	 STATE OF WASHINGTON
	  	 )

	 	  	 ) ss.

	 COUNTY OF KING
	  	 )

  
 I certify that I know or have
satisfactory evidence that James A. Johnson signed this instrument, on oath stated that he was authorized to execute the instrument and acknowledged it as the Senior Vice President and Chief Financial Officer of ZymoGenetics, Inc. to
be the free and voluntary act of such party for the uses and purposes mentioned in the instrument. 
  
 Dated: June 11, 2004. 
  

	
	 /s/ Carol A. Alto

	 (Signature)

	
	 Notary Public

	 Title

	
	 My appointment expires March 7, 2006

  

 2 

			
	 STATE OF CALIFORNIA
	  	 )

	 	  	 ) ss.

	 COUNTY OF LOS ANGELES
	  	 )

  
 I certify that I know
or have satisfactory evidence that Peter J. Nelson is the person who appeared before me, and said person acknowledged that he/she signed this instrument, on oath stated that he/she was authorized to execute the instrument and acknowledged it as the
Chief Financial Officer of ARE-QRS Corp., general partner of Alexandria Real Estate Equities, L.P., the Managing Member of ARE-1208 Eastlake Avenue, LLC, to be the free and voluntary act of such party for the uses and purposes mentioned in this
instrument. 
  
 DATED: July 19, 2004. 
  

	
	 /s/ Shelly A. Kroll

	 (Signature of Notary Public)

	
	 Shelly A. Kroll

	 (Printed Name of Notary Public)

	
	 My Appointment expires: August 10, 2006

  

 3Amendment to 6 August 1982 Insulin Agreement, dated May 18, 2004

 Exhibit 10.3 
  
 Amendment to 6 August 1982 Insulin Agreement 
  
 This Amendment of May 18, 2004 (“Amendment Agreement”) to the Insulin Agreement and the 1987 Agreement (as defined below) is
entered into between Novo Nordisk A/S, a Danish corporation having a principal place of business at Novo Alle, DK-2880, Bagsvaerd, Denmark (“Novo Nordisk”) and ZymoGenetics Inc., a Washington Corporation having a principal place of
business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (“ZGI”). 
  
 WHEREAS: 
  

	 	(A)	ZGI (formerly known, and for convenience referred to herein, as Zymos Corporation) and Novo Industri A/S (the predecessor corporation to Novo Nordisk) entered into an insulin
agreement dated 6 August 1982, as amended (“Insulin Agreement”) relating to recombinant production of human insulin and an amendment agreement dated 13 March 1987 relating to human glucagon, as amended (including the restatement thereof
made in November 2000) (“1987 Agreement”). 

  

	 	(B)	Under the Insulin Agreement ZGI would receive annual payments with respect to each successive twelve (12) month period commencing on the first date of the First Commercial Sale (as
defined in the Insulin Agreement).  

  

	 	(C)	ZGI and Novo Nordisk desire to amend the Insulin Agreement and to specify in this Amendment Agreement the payment terms which have been applied and will continue to be applied in
respect of the royalties due under the Insulin Agreement and the 1987 Agreement. 

  
 NOW IT IS HEREBY AGREED AS FOLLOWS: 
  

	 	1.	Section 1 of the Insulin Agreement shall be deemed to be amended by the addition of a new definition “Calendar Quarter” to read as follows: 

  
 “Calendar Quarter shall mean each of the respective three-month periods
ending March 31, June 30, September 30, and December 31 of each year.” 
  

	 	2.	With respect to Sections 5(c)(1)(ii); 5(c)(2)(i); and 7(c) of the Insulin Agreement and Section C.1 of Exhibit B to the Insulin Agreement; and Section 2(a)(ii) of the 1987
Agreement, each reference in such sections to “Participation Year” shall be deleted in its entirety and replaced by “Calendar Quarter”. 

	 	3.	With respect to clauses (aa) – (dd) of Section 5(c)(2)(i) of the Insulin Agreement, each reference to “in such Year” shall be deleted in its entirety and replaced by
“in the Participation Year in which such Calendar Quarter occurs”. With respect to clause (ee) of Section 5(c)(2)(i) of the Insulin Agreement, each reference to “during each such Year” and “During Such Year” shall be
deleted in its entirety and replaced by “during such Calendar Quarter”. 

	 	4.	Section 7(a) (i) of the Insulin Agreement shall be amended in its entirety to read as follows: 

  
 “Section 7(a)(i). Novo shall deliver to Zymos within 60 days of the end of each Calendar Quarter a written accounting
showing its computation of payments due for such Calendar Quarter. Novo shall pay to Zymos all payments due for each Calendar Quarter within 60 days of the end of such Calendar Quarter. 

	 	5.	The changes to Section 7(a)(i) and Section 7(c) of the Insulin Agreement under this Amendment Agreement shall apply with equal force to Section 3 of the 1987 Agreement.

  

	 	6.	The remainders of the Insulin Agreement and the 1987 Agreement remain unchanged by this Amendment Agreement. 

  
 IN WITNESS WHEREOF, ZGI and Novo Nordisk have caused this Amendment Agreement to be executed
in duplicate in their names by their properly and duly authorized officers or representatives. 
  

			
	 NOVO NORDISK A/S
	 	 ZYMOGENETICS, INC.

		
	 /s/ Jesper Brangaard, CFO

	 	 /s/ James A. Johnson, CFO

	 Name:
	 	 Name:

	 Title:
	 	 Title:

		
	 NOVO NORDISK A/S
	 	 
		
	 /s/ Kare Schultz, COO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]